New antibody therapy shows promise in managing condition
Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab (BRIUMVI®) for the treatment of relapsing-remitting multiple sclerosis (RRMS).
This approval marks a significant milestone for the European specialty pharmaceutical company.
“Today’s milestone reflects our commitment to improving the lives of people living with MS in the UK,” said Mark Slater, UK General Manager of Neuraxpharm.
Ublituximab, developed by TG Therapeutics and licensed by Neuraxpharm outside the US, targets CD20-expressing B cells. Clinical studies show it significantly suppresses relapses and disease activity measured by MRI, compared with oral teriflunomide.
“NICE’s decision to recommend BRIUMVI® for RRMS endorses its therapeutic potential and highlights its ability to make a meaningful difference for people living with MS,” said Dr Jörg-Thomas Dierks, CEO of Neuraxpharm. The treatment, administered twice a year, is expected to provide an effective solution for many patients and healthcare providers.
The therapy works by targeting B cells, a type of white blood cell involved in the immune system’s attack on nerve cell protection in multiple sclerosis. This action reduces relapse chances, relieves symptoms and slows disease progression.
The approval follows Neuraxpharm’s agreement with TG Therapeutics in August 2023 to commercialise ublituximab outside the US, Canada, and Mexico. NICE’s cost comparison suggests ublituximab offers similar benefits to and lower costs than other anti-CD20 treatments like ocrelizumab and ofatumumab. This decision recommends the use of the least expensive options available.
Neuraxpharm’s efforts signify a pivotal step in advancing multiple sclerosis treatments and improving patient outcomes.
